Lantern Pharma Return on Equity

Lantern Pharma (LTRN) currently reports a ROE of 532161.34%. That is above the Healthcare sector average of 22.01%. Use the charts on this page to explore Lantern Pharma's ROE history and peer comparisons.

Lantern Pharma's ROE of 532161.34% is higher than the Healthcare sector average of 22.01%. That is roughly 2417750.1% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Lantern Pharma's current 532161.34% should be judged against Healthcare norms (sector average: 22.01%) and against LTRN's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 532161.34%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 22.01%. From there, open related valuation or income-statement pages for Lantern Pharma, and consider following LTRN for alerts when major investors trade the stock.

Lantern Pharma is classified in the Healthcare sector. On ROE, it currently shows 532161.34% versus a sector average near 22.01%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LTRN with unrelated industries.